R&D at Almirall

We aim to bring deliver breakthrough innovation in the field of dermatology to address patient’s unmet needs.

By blending internal capabilities and know-how with our partners’ expertise, we ensure that we develop solutions offering the most appropiate approaches for each disease. Inspired by science and devoted to patients, this is the best way to ensure the long-term fulfilment of our purpose.

Our Purpose

Our therapeutic focus

Medical dermatology, focusing on specific conditionswith substantial unmet needs.

Our Legacy

Almirall’s history of more than 50 years in R&D is reflected in the number of therapeutic solutions that have been brought to market across several therapeutic areas over the years.

Aclidinium bromide
Aceclofenac
Almagate
Almotriptan

Cinitapride
Clebopride
Ebastine

These treatments have contributed to improving the lives of millions of people worldwide across more than 70 countries.

A global footprint through our medicines

(*)Worldwide rights to the respiratory f Respiratory Franchise worldwide rights were transferred to AstraZeneca in 2014.

Our capabilities

At Almirall, we devote significant and expertise to building and advancing our pipeline of future products. We invest around 10-12% of our annual net sales in R&D, dedicate15 % of our workforce (approximately260 scientists) to research and development activities and operate three cuttingedge R&D centres located in Spain, Germany and the US.

Meet the expert

Our pipeline

Our way of doing R&D marks our commitment

Commitment to patients

We test and weand share. By providing accessible clinical trial information, we are committingcommitted to helping people — including healtcare professionals, medical practitioners, patients, and their families — improvinge their knowledge standing of healthcare testing and results.clinical research and its outcomes.

Go to Clinical trials